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Abstract
Macronutrient intake, the proportion of calories consumed from carbohydrate, fat, and protein, is 
an important risk factor for metabolic diseases with significant familial aggregation. Previous 
studies have identified two genetic loci for macronutrient intake, but incomplete coverage of 
genetic variation and modest sample sizes have hindered the discovery of additional loci. Here, we 
expanded the genetic landscape of macronutrient intake, identifying 12 suggestively significant 
loci (P < 1 × 10−6) associated with intake of any macronutrient in 91,114 European ancestry 
participants. Four loci replicated and reached genome-wide significance in a combined meta-
analysis including 123,659 European descent participants, unraveling two novel loci; a common 
variant in RARB locus for carbohydrate intake and a rare variant in DRAM1 locus for protein 
intake, and corroborating earlier FGF21 and FTO findings. In additional analysis of 144,770 
participants from the UK Biobank, all identified associations from the two-stage analysis were 
confirmed except for DRAM1. Identified loci might have implications in brain and adipose tissue 
biology and have clinical impact in obesity-related phenotypes. Our findings provide new insight 
into biological functions related to macronutrient intake.
Introduction
Macronutrient intake refers to the proportion of calories consumed from carbohydrate, fat, 
and protein dietary sources and is an important modifiable risk factor for prevalent diseases 
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such as obesity, type 2 diabetes (T2D), cardiovascular disease (CVD), and cancer [1]. The 
relevance of macronutrient intake and dietary quality for disease prevention is reflected by 
related goals across numerous public health guidelines such as the U.S. Department of 
Health and Human Services’ 2015–2020 Dietary Guidelines for Americans [2–5]. 
Macronutrient intake, and eating behavior in general, is an excellent example of a complex 
trait involving the simultaneous interplay among environmental, physiological, and genetic 
factors [6]. Genetic analyses of eating behavior, including those in family studies, have 
suggested that the familybased heritability of macronutrient intake ranges between 20–40% 
[7]. This information has generated interest in pinpointing specific genetic loci that influence 
macronutrient intake [7, 8].
Previous genome-wide association (GWA) study for macronutrient intake have identified 
associations between a genetic variant mapping near the fibroblast growth factors 21 gene 
(FGF21) [9]. The FGF21 locus is associated with diets higher in carbohydrate and alcohol, 
and lower in fat and protein [9, 10]. Functional characterization studies have linked this 
locus with regulating food intake, macronutrient preference, and central reward pathways 
[11]. Earlier GWA investigations have also provided evidence for the association between an 
obesity and fat-mass associated locus (FTO) with protein intake, where individuals carrying 
the BMI-raising allele reported diets higher in protein [9, 12].
Investigations of other complex traits, where common genetic variants have been shown to 
exert modest effects, suggest that attaining a larger sample size and improving genotyping 
coverage may help identify novel associations [13–15]. Thus, to advance our understanding 
of the genetic architecture of macronutrient intake, we conducted comprehensive GWA 
meta-analyses for percentage of total energy intake from carbohydrate, fat, and protein using 
1000 Genomes Project-based imputation (minor allele frequency (MAF) in the range of 0.5–
5% [14]) in 91,114 European ancestry participants representing 24 cohorts. We performed a 
two-stage analysis where the suggestive loci from the discovery stage were subsequently 
examined in a replication meta-analysis of 32,545 additional participants from five 
independent epidemiologic cohorts. The significant loci from this combined analysis were 
investigated in additional analysis of 144,770 participants of the UK Biobank. Finally, we 
applied an array of complementary computational approaches to investigate potential 
mechanistic functions of the novel loci associated with macronutrient intake.
Methods
Study populations
GWA included 91,114 European ancestry participants from 24 epidemiologic cohorts from 
the CHARGE Consortium Nutrition Working Group (Supplemental Table S1). In silico 
replication was conducted in 32,545 additional European ancestry participants from five 
epidemiologic cohort studies. Participants in discovery and replication analyses for EPIC-
Norfolk and Fenland cohort studies did not overlap. Additional verification for replicated 
genetic variants were conducted in association analyses of up to 144,770 European ancestry 
participants with genetic and macronutrient intake information of the UK Biobank [16]. 
Participants provided written informed consent, and each cohort’s study protocol was 
reviewed and approved by their respective institutional review board.
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Assessment of macronutrient intake
Assessment tools to estimate habitual dietary intake in the participating cohorts including 
validated cohort-specific food frequency questionnaires (FFQ), diet history and diet records 
(Supplemental Table S2). The FFQ used by each cohort was tailored to best capture the 
dietary habits of the specific population under study. Based on the responses to each dietary 
assessment tool and study-specific nutrient databases, habitual nutrient consumption was 
estimated. Daily total energy intake was estimated from the sum of intakes of carbohydrate, 
fat, protein, and alcohol. The present analysis focused on the percentage of total energy 
intakes from carbohydrate, fat, and protein. Over-reporters and under-reporters were 
excluded by standard cut-offs determined by each study cohort as part of quality control [9].
Genotyping
Genome-wide genotyping was conducted using Affymetrix or Illumina platforms. Each 
study performed quality control for genotyped variants based on MAF, call rate, and 
departure from Hardy-Weinberg Equilibrium (Supplemental Table S3). Phased haplotypes 
from 1000G were used to impute ~38 million autosomal variants using a Hidden Markov 
Model algorithm implemented in MACH/minimac [17, 18] or SHAPEIT/IMPUTE [19, 20]. 
Variants with low minor allele count (MAC < 20) and low imputation quality (<0.4) were 
removed. The number of autosomal genetic variants analyzed in this study was ~11.8 
million.
Statistical analysis
Discovery and replication meta-analysis—Study-specific GWA analyses were 
conducted for each macronutrient using genotyped and imputed genotypes dosages 
assuming an additive genetic model using continuous allelic dosage values between 0 and 2. 
The basic model included age and sex for all studies, and study-specific covariates (e.g., 
study site) and population stratification principal components, where applicable. In a second 
model, BMI was added to the covariates to decrease variance of the macronutrient 
phenotypes and to account for genetic effects mediated through body composition. Since 
each study estimate of macronutrient consumption are comparable, the results from each 
study were combined in a fixed-effect meta-analysis with inverse variance weighting using 
METAL (version—released 25 March 2011) software [21]. To address additional inflation 
due to population stratification, the association results from individual studies as well as 
meta-analyses were adjusted for genomic control. Following the meta-analysis, genetic 
variants with low MAF (<0.5%) or those missing data from more than half the samples were 
removed. Heterogeneity across studies was tested by using Cochran’s Q statistic and 
quantified using the heterogeneity statistic, I2, and presented as %. Genome-wide 
significance was considered at the standard genome-wide Bonferroni-corrected threshold of 
P < 5 × 10−8 given that we studied three partially correlated traits. In addition, we used 
summary statistics from the discovery basic model GWA analyses to estimate single 
nucleotide polymorphism (SNP)-based heritability of each macronutrient intake using LD 
score regression (LDSC) [22].
To confirm the associations of loci from the GWA meta-analyses, an in silico replication of 
12 variants with suggestive significance (P < 1 × 10−6) was conducted in five independent 
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epidemiologic cohort studies. We pursued replication of hits for the strongest corresponding 
association from the discovery analysis (i.e., macronutrient and BMI-adjusted or unadjusted 
model). Significant replication was considered at a Bonferroni-corrected threshold of 
P1sided < 4.17 × 10−3 (=0.05/12 loci). The results from the GWA results from the discovery 
and replication cohort studies were combined using a fixed-effect inverse variance-weighted 
meta-analysis using METAL software. For this combined analysis, genome-wide 
significance was also considered at the genome-wide Bonferroni-corrected threshold of P < 
5 × 10−8. In addition, we performed follow-up analyses of the replicated genetic variants in 
the UK Biobank in unrelated subjects of white British ancestry with dietary data using 
PLINK [23] linear regression and an additive genetic model adjusted for age, sex, 10 PCs, 
genotyping array, and BMI (if warranted) to determine SNP effects on macronutrient intake. 
Similarly, we performed meta-analyses including the combined analysis (discovery and 
replication epidemiologic cohorts) and the UK Biobank.
Biological insights—To determine whether any of our identified genetic variants might 
be tagging potentially functional variants, we identified all variants within 1 Mb window and 
in LD (r2≥ 0.8) with our replicated-index variants. We then annotated all identified tagging 
variants using ANNOVAR [24]. To predict functional elements likely to be phenotypically 
relevant we used LINSIGHT, a computational method that combines a generalized linear 
model for functional genomic data with a probabilistic model of molecular evolution [25]. 
Next, we aimed to identify a set of 99% credible causal variants for the lead independent 
variants at novel loci using PAINTOR, a probabilistic framework that integrates association 
strength with genomic functional annotation data to improve accuracy in selecting plausible 
causal variants for functional validation [26]. We used regional association plots to define 
the locus boundaries in each region comprising the lead genetic variant. We identified the 
outermost variants from the set of variants in r2 ≥ 0.4 with the lead genetic variant. We set 
the maximal number of causal genetic variants in each region to three. Next, we conducted 
colocalization of genetic variants in regions encompassing the newly associated lead variants 
based on regional plots with expression quantitative trait loci (eQTL) using genotype-tissue 
expression (GTEx) database [27]. Finally, we used public available data from an atlas of the 
human long non-coding RNAs (lncRNAs), a comprehensive atlas with substantially 
improved gene models that integrates new data from gene expression, evolutionary 
conservation and genetic studies models allowing to better assess the diversity and 
functionality of these RNAs [28].
Cross-phenotype associations and causal inference analysis—To understand the 
pathways which new loci might be related to macronutrient intake, we examined the 
associations of the two new and two known macronutrient intake regions with a wide range 
of risk factors, molecular traits and clinical disorders, using Phenoscanner [29], which 
encompasses 137 genotype-phenotype datasets from the NHGRI-EBI GWAS catalog and 
other databases. We set a Bonferroni-corrected threshold for significance at P < 3.6 × 10−4 
(=0.05/137 phenotypes). Since the top hit at DRAM1 was only available for inflammatory 
diseases in Phenoscanner, we looked for association with other metabolic traits in the T2D 
Knowledge Portal and set a nominal p-value for significance [30]. We also used LD score 
regression [31] to estimate the genetic correlations between macronutrient intake and a range 
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of disease outcomes and intermediate traits relating to food choice and eating behaviors 
(psychiatric traits, eating disorders, and used years of education as a surrogate for 
socioeconomic status) and cardiometabolic traits (BMI, glycemic traits, T2D, blood lipids, 
and coronary artery disease). Bidirectional Mendelian randomization (MR) was 
subsequently used to examine causality between traits found to have a significant genetic 
correlation. In MR analyses, our genetic instrument comprised of genetic variants associated 
with the proportion of protein intake that achieved genomewide significance in the combined 
discovery + replication + UK Biobank meta-analyses. The genetic proxy for protein intake 
thus included the FGF21 locus. Since the same FGF21 genetic variant is a genetic proxy for 
fat and carbohydrate intake, we additionally evaluated whether the genetic effect on fat or 
carbohydrate intake raised BMI. BMI effect sizes were extracted from the largest published 
GWA meta-analysis for BMI of predominantly European ancestry participants [32], and 
supplemented with data from additional UK Biobank participants. We performed fixed-
effect inverse variance-weighted meta-analysis [33], median and weighted median [34], and 
MR Egger approaches where we identified potential pleiotropy.
Data availability
Summary statistics of all analyses are available in dbGaP (accession number phs000930).
Results
Discovery GWA meta-analyses of percentage of total energy intake from carbohydrate, fat, 
and protein were conducted with participants from 124 epidemiologic cohort studies of the 
CHARGE Consortium. General characteristics of participating cohort studies are presented 
in Supplemental Table S4. Mean macronutrient intake distribution was 48.5% ± 8.4, 32.1% 
± 6.7, and 17.8% ± 3.6 for carbohydrate, fat and protein intake, respectively, and was 
consistent with earlier estimates of macronutrient intake distribution [9, 12] including those 
from population-based survey studies [35]. Figure 1 represents a schematic of the study 
design and main findings.
Discovery GWA meta-analysis
In discovery analyses, we tested the association of ~11.8 million genetic variants (MAF > 
0.5%, imputation quality >0.4) in 91,114 participants of European ancestry with 
macronutrient intake. Twelve independent loci, three at genome-wide significance (P < 5 × 
10−8) and nine at subgenome wide significance (P < 1 × 10−6), showed associations with 
macronutrient intake either with or without BMI adjustment (Table 1; Supplemental Figure 
S1; Supplemental Figure S2). Estimated genetic effects sizes per each copy of the minor 
allele are detailed in Table 1 and Supplemental Table S5. Estimated SNP-based heritability 
was 3.9, 3.3, and 3.2% for carbohydrate, fat, and protein, respectively.
Replication meta-analysis
In silico replication was conducted for the set of 12 independent loci identified in the 
discovery meta-analyses. Replication included 32,545 additional participants of European 
ancestry from five epidemiologic cohort studies.
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The distribution of macronutrient intake in the replication studies was consistent with the 
discovery studies (Supplemental Table S4). In total, four independent loci including two 
novel hits in Retinoic Acid Receptor Beta (RARB) locus, and DNA Damage Regulated 
Autophagy Modulator 1, (DRAM1) locus, and two previously known (FGF21 and FTO) 
were confirmed in the subsequent two-stage replication of discovery findings (Table 2; 
Supplemental Table S6). Specifically, we replicated the association between rs7619139 in 
RARB locus and higher carbohydrate intake (β= 0.20% per each copy of the minor allele, 
SE = 0.052, Preplication = 4.0 × 10−5), achieving genomewide significance in the combined 
meta-analysis including GWA results from the discovery and replication cohort studies (β= 
0.20%, SE = 0.031, Pcombined = 4.13 × 10−11) (Table 2). Similarly, the association between 
rs77694286 in DRAM1 locus and higher protein intake was significant in the replication 
analysis (β= 0.55% per each copy of the minor allele, SE = 0.194, Preplication = 2 × 10−3) and 
also achieved genome-wide significance in the combined metaanalysis (β= 0.56%, SE = 
0.092, Pcombined = 1.90 × 10−9). In addition, we confirmed the previously reported 
associations between the FGF21 locus (rs838133) and intake for all macronutrients, and the 
FTO locus (rs1421085) and higher protein intake (Table 2).
UK Biobank analysis
In analysis of the UK Biobank, three of the four loci achieved the Bonferroni-corrected 
threshold for significance. We noted similar effect sizes and directionality for RARB locus 
and higher carbohydrate intake (β= 0.17% per each copy of the minor allele, SE = 0.049, P = 
4.60 × 10−4). The association between FGF21 and FTO loci and macronutrient intake was 
also confirmed with effect sizes similar to the combined analyses (Table 2). We were unable 
to confirm the association between the lead DRAM1 signal and higher protein intake in the 
UK Biobank (β=−0.17% per each copy of the minor allele, SE = 0.12, P = 0.16) or any other 
genetic variants in LD with the lead signal (results not shown). A meta-analysis including 
discovery cohorts, replication cohorts and the UK Biobank (n = 268,429) showed consistent 
evidence for RARB, FTO, and FGF21 loci (Table 2). The DRAM1 association with protein 
intake in this meta-analysis showed significant evidence of substantial heterogeneity (I2 = 
91%) likely a result of the 1% MAF.
Biological insights
Figure 2 summarizes biological insights for the two variants identified for macronutrient 
intake. The lead genetic variant in RARB locus (rs7619139) is located in a lncRNA 
(AC133680.1), while the lead DRAM1 signal (rs77694286) is an intronic variant in DRAM1 
gene. Using ANNOVAR, we did not find evidence for coding variants close to (<1Mb) and 
in linkage disequilibrium (LD) (r2> 0.8) with our two index variants. We next applied 
LINSIGHT and showed that the lead variant at RARB locus is a highly constrained variant 
(median LINSIGHT score of 0.958), indicating a 95.8% probability of fitness consequences 
due to mutations at this nucleotide site (Supplemental Figure S3). No evidence of a 
constrained variant was detected for the DRAM1 signal.
To identify 99% credible sets of causal variants for each lead variant at the novel loci, we 
identified the outermost variants from the set of variants in r2 ≥ 0.4 with the lead variant 
using regional association plots to define the locus boundaries. The 99% credible sets 
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included 102 and 127 variants for the RARB and DRAM1 loci, respectively. The lead 
variant at RARB was the best-ranked variant in the region (posterior probability = 0.99 and 
Z-score = 4.63). The variant is annotated as a functional variant with a high CADD score 
[Combined Annotation Dependent Depletion (CADD) score = 21.1], a score that integrates 
multiple annotations into one metric by contrasting variants that survived natural selection 
with simulated mutations [36], and was predicted to be deleterious (Supplemental Figure 
4A). For DRAM1, the GWA signal as well as two other variants (rs58512731 and 
rs78927281) in perfect LD with the lead variant are the most likely causal variants in the 
region. These variants lie in super-enhancers of DRAM1 (super-enhancer 32592) 
(Supplemental Figure 4B). In an eQTL analysis of regions encompassing the newly 
associated lead variants, we did not detect any significant eQTL for RARB within the high 
LD window. However, the allele associated with higher protein intake in DRAM1 region 
was associated with lower expression of DRAM1 in several tissues including subcutaneous 
adipose tissue (P = 5.1 × 10−8), artery (P = 2.9 × 10−7), esophagus (P = 6.5 × 10−10), left 
ventricle (P = 1.6 × 10−8), skin (P = 5.6 × 10−8) and tibial nerve (P = 3.1 × 10−8) 
(Supplemental Table S7). Finally, we integrated data from the Atlas of the Human lncRNAs 
to gain insights from the lead GWA hit at RARB locus lying in the lncRNA AC133680.1. 
We observed that the lncRNA is differentially expressed in several brain regions [the 
strongest being in the caudate nucleus (39.3 fold-change increase), and plays a role in H1-
neuronal progenitor cells differentiation (3.7 fold-change increase, false discovery rate 
(FDR) at 5% P = 1.03 × 10−3), as well as cardiomyocyte (5.5 fold-change increase, FDR at 
5% P = 3.87 × 10−4), and melanocyte differentiation (2.9 fold-change increase, FDR at 5% P 
= 3.22 × 10−3)] (Supplemental Table S8, Supplemental Figure S5).
Cross-phenotype associations of significant loci
To investigate the clinical importance of the macronutrient intake loci, we examined the 
associations of the identified loci with a range of disease risk factors, molecular traits, and 
clinical disorders. The RARB rs7619139 T-allele associated with higher carbohydrate intake 
was also associated with lower BMI (β=−0.019, SE = 0.004, P = 3.32 × 10−6) (Supplemental 
Table S9). The DRAM1 rs77694286 G-allele associated with higher protein intake displayed 
significant association with higher T2D risk (OR = 1.89, (95%CI: 1.36–2.54); P = 0.019). 
Associations for the FGF21 and FTO loci are also listed in Supplemental Table S9.
Genetic correlation and causal inference analysis
We examined the genetic correlation between macronutrient intake and a range of disease 
outcomes and intermediate traits using LDSC. We found an inverse genetic correlation 
between the intake of carbohydrate and fat (r =−0.78; P < 0.001), carbohydrate and protein 
(r =−0.33; P < 0.001), but not fat and protein. (Supplemental Figure S6). We found a 
moderate concordant genetic correlation between protein intake and BMI (rg = 0.23, P = 4 × 
10 −4 ; Supplemental Figure S6). Also, we found an inverse genetic correlation between 
dietary fat intake and years of education (rg =−0.24, P = 5 × 10−4; Supplemental Figure S6). 
Upon identifying a significant genetic correlation between higher protein intake and higher 
BMI, we used a bi-directional MR approach to investigate whether genetically driven 
protein intake has a causal role for BMI and vice versa. We found that genetically raised 
protein intake (per 1% of total energy intake) was associated with higher BMI (β= 0.09 
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kg/m2, SE = 0.03, P = 6.92 × 10−4) (Table 3). Given that the lead variant at FGF21 was 
associated with all three macronutrients, it is possible that any one of the macronutrients 
might genetically raise BMI. Conversely, we also noted that genetically determined higher 
BMI increased the amount of protein intake, but not carbohydrate or fat intake (Table 3). A 
one standard deviation (1-SD) increase in BMI due to a 93-variant polygenic risk score 
(excluding FTO) was associated with 0.58% higher protein intake (SE = 0.08, P = 9.88 × 
10−13) (Table 3, Supplemental Figure S7).
Discussion
In this study including data from up to 91,114 participants from European ancestry, we 
identified 12 suggestively significant loci (P < 1 × 10−6) associated with macronutrient 
intake including four genome-wide significant loci in combined meta-analysis from 
discovery and replication cohort studies. Meta-analysis including up to 123,659 individuals 
supported a novel common variant in RARB locus associated with 0.20% higher 
carbohydrate intake, a novel rare variant in the DRAM1 locus (MAF = 1% associated with 
0.55% higher protein intake, and corroborated previous findings between FGF21 with higher 
carbohydrate intake and lower fat and protein intake, and FTO with higher protein intake [9, 
12]. In additional analysis of 144,770 participants from the UK Biobank, all identified 
associations from the two-stage analysis were confirmed except for DRAM1, which 
warrants further investigation given its 1% MAF. The identified loci are predicted to be 
relevant regulatory regions mainly functional in brain and subcutaneous adipose tissues. The 
clinical translation of these variants is supported by the associations with obesity related-
traits.
Suboptimal diets represent a major driving force behind escalating obesity epidemic 
worldwide and their associated risk of T2D, CVD, and cancer [37]. Ecologic studies suggest 
that increasing intake of carbohydrates, especially added sugars, is most strongly linked to 
these trends [38, 39]. The present analysis suggests that a regulatory common genetic variant 
in the RARB locus, situated in the lncRNA AC133680.1, is associated with increased 
carbohydrate intake. The RARB locus has been identified as a novel obesity locus in a 
recent GWA meta-analysis for BMI [32]. Fine-mapping confirmed that the identified variant 
in this study, in high LD with the BMI reported variant (rs6804842, LD = 0.89), is likely to 
be the causal variant in the region. We showed that the identified variant is differentially 
expressed in several brain regions, where the strongest association was seen for caudate 
nucleus (39.3 fold-change increase). In humans, ingestion of high-density and palatable 
food, such as added sugar foods, has been shown to release dopamine in the caudate and 
putamen regions [40]. Still, the potential functional overlap between the lncRNA 
AC133680.1 and other relevant genes in the region supports further explorations of 
biological implications. Our findings may serve as preliminary evidence for the design and 
implementation of in vitro and in vivo experimentations investigating how this genetic 
variant might contribute to food selection in humans. In this regard, the identification and 
characterization of relevant macronutrient intake genes, such as FGF21, has contributed 
evidence that help create the framework to develop an FGF21 analogue that has been shown 
to suppress sugar intake, sweet taste preference, and decrease central reward pathways when 
administered in monkeys with obesity and humans with obesity and T2D [11].
Merino et al. Page 8













In this study, we used 1000G imputation reference panel which allowed us to identify a rare 
variant in DRAM1 locus for the association with protein intake. DRAM1 encodes the DNA 
damage regulated autophagy modulator, a lysosomal protein that is required for induction of 
autophagy by the p53 pathway [41]. Through genetic fine mapping, we showed that the 
GWA hit is the most likely causal variant in the region together with other two variants in 
perfect LD with the lead variant. These variants lie in a super-enhancer region of DRAM1 
(super-enhancer 32,592), and the protein increasing G-allele in rs77694286 is associated 
with higher T2D risk and lower expression of DRAM1 in subcutaneous adipose tissue. The 
association between DRAM1 and protein intake was not verified in additional analysis of 
144,770 subjects from the UK Biobank. A potential explanation for the lack of confirmation 
of the DRAM1 findings in the UK Biobank may be due the MAF of this variant. Therefore, 
our observation linking DRAM1 with protein intake requires further evaluation.
In our discovery analysis, worth noting is a novel genome-wide signal in the ABO locus for 
protein intake that did not replicate in subsequent analyses. This variant is in perfect LD 
with an intronic genetic polymorphism in the ABO gene (rs651007) and associates with a 
host of cardiometabolic traits including higher fasting glucose levels and moderate increases 
in T2D risk [42]. A recent study has also identified that the minor allele at this 
polymorphism significantly interacts with higher dietary fat intake to exacerbate BMI [43]. 
Pending replication of the interaction observation and the present ABO association with 
protein intake, these observations may be utilized for future studies to better understand the 
genetic architecture of macronutrient intake and related metabolic outcomes.
The observation of a moderate concordant genetic correlation between protein intake and 
BMI, but not other obesity-related traits, suggests that genetic effects of higher protein 
intake are shared with greater BMI genome-wide. First, we observed reasonably clear 
evidence to support causality for BMI with protein intake. However, since our GWA were 
with and without adjustment for BMI, we cannot exclude the potential for BMI-related bias 
(i.e. reporting bias in those who are overweight or obese) to account for our current MR 
observations [44]. A previous report highlighted that the FTO locus was associated with 
higher protein intake [45], a finding we now extend to other BMI-raising alleles, suggest 
that higher BMI is associated with higher reported protein intake not specific to the effect of 
FTO (Supplemental Figure S6). Second, for our MR analysis, the lead variant at FGF21 
associated with percentage of energy intake from protein was also associated with 
percentage of energy from carbohydrate and fat intake, therefore we cannot ascribe causality 
between one specific macronutrient group with BMI or whether this reflects substitution of 
macronutrients as a proportion of total energy intake. A meta-analysis of randomized 
controlled trials demonstrated that diets with any macronutrient composition result in weight 
loss [46]. However, given that the current macronutrient intake genetic predisposition is 
limited to a few number of variants, future research using more genetically increased 
macronutrient consumption is needed to confirm these findings.
In the U.S., dietary factors are estimated to account for >650,000 deaths per year and 14% of 
all disability-adjusted life-years lost [47]. The nutritional shift towards increased 
consumption of ultra-processed foods has been a consequence of globalization and rapid 
economic development during the last few decades [48]. Family-based heritability estimates 
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for macronutrient intake ranges between 20–40 %, whereas SNP-based heritability reported 
previously [9] and here indicate more modest heritability estimates. Although the small 
estimates indicate environmental variation plays a major role in explaining the remainder of 
the trait, genes still have a role in explaining a significant proportion of macronutrient intake 
heritability. Our analysis indicates shared genetic correlations across macronutrients, 
particularly carbohydrate with both fat and protein. Understanding the biological basis of 
dietary intake can help guide future studies and shape public health initiatives. Our results 
may be used to assess dietary pattern recommendations based on genetic risk profile, or may 
be used by recall-by-genotype studies to evaluate whether a dietary pattern tailored to an 
individual’s genetic risk will lead to more desirable health outcomes. Nevertheless, there are 
several challenges in identifying and validating genetic associations for macronutrient intake 
worth noting. Variability in dietary intake across geographical locations, error in dietary 
assessment, differences in allele frequencies across studies, imperfect imputation within 
studies, and ancestry-specific LD patterns may hinder discovery and replication of genetic 
associations and could potentially induce false positive findings. In addition, noting the 
variability in dietary habits across populations and the use of dissimilar dietary assessment 
tools across studies is particularly relevant for meta-analyses of lifestyle traits [49]. 
Although the present investigation was limited to individuals of European ancestry for the 
purpose of reducing ancestry-specific LD patterns, we cannot account for differences in 
other intrinsic factors across studies. In addition, the present findings require further 
validation in individuals of other ancestries. Finally, because we studied three partially 
correlated traits, we set the p-value for statistical significance at the genome-wide 
Bonferroni-corrected threshold of P < 5 × 10−8, and whether a more stringent threshold is 
more appropriate for partially correlated traits is unclear.
In summary, our results provide compelling novel evidence of the genetic architecture of 
macronutrient intake and contribute biological insights relating dietary intake to the central 
nervous system and adipose tissue biology. Our findings add to the current understanding of 
macronutrient intake and are hypothesis-generating for future studies.
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Schematic of the study design and main findings
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Biological insight of the two replicated variants in CHARGE. Data generated from an array 
of complementary approaches including genetic fine-mapping, epigenetic regulation and 
expression data to investigate the biological relevant of novel variants. Through genetic fine 
mapping, we showed that the lead variant at RARB locus associated with CHO intake was 
the best-ranked variant in the region. This variant is placed in a lncRNA, is a highly 
constrained variant and predicted to be deleterious. We showed that the lncRNA gene is 
differently expressed in several brain regions and is involved in neuronal progenitor cells 
differentiation. For DRAM1, the GWA hit is predicted to be the most likely causal variant in 
the region and lie in a superenhancer of DRAM1 (super-enhancer 32592). Gene-tissue 
expression showed that the allele associated with higher protein intake was associated with 
lower expression (rank normalized expression) of DRAM1 in subcutaneous adipose tissue 
(A/A; Homozygote reference, n = 359. G/A; Heterozygote, n = 29, G/G; Homozygote 
alternate, n = 1). The clinical transcendence of the two identified loci in CHARGE is 
supported by the association with obesity-related traits. DRAM1 findings did not replicate 
when using data from the UK Biobank data alone
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